Suppr超能文献

射血分数保留的心力衰竭精准医学的创新临床试验设计

Innovative Clinical Trial Designs for Precision Medicine in Heart Failure with Preserved Ejection Fraction.

作者信息

Shah Sanjiv J

机构信息

T1 Center for Cardiovascular Therapeutics, Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

出版信息

J Cardiovasc Transl Res. 2017 Jun;10(3):322-336. doi: 10.1007/s12265-017-9759-8. Epub 2017 Jul 5.

Abstract

A major challenge in the care of patients with heart failure and preserved ejection fraction (HFpEF) is the lack of proven therapies due to disappointing results from randomized controlled trials (RCTs). The heterogeneity of the HFpEF syndrome and the use of conventional RCT designs are possible reasons underlying the failure of these trials. There are several factors-including the widespread adoption of electronic health records, decreasing costs of obtaining high-dimensional data, and the availability of a wide variety of potential therapeutics-that have evolved to enable more innovative clinical trial designs in HFpEF. Here, we review the current landscape of HFpEF RCTs and present several innovative RCT designs that could be implemented in HFpEF, including enrichment trials, adaptive trials, umbrella trials, basket trials, and machine learning-based trials (including examples for each). Our hope is that the description of the aforementioned innovative trial designs will stimulate new approaches to clinical trials in HFpEF.

摘要

射血分数保留的心力衰竭(HFpEF)患者护理中的一个主要挑战是,由于随机对照试验(RCT)结果令人失望,缺乏经过验证的治疗方法。HFpEF综合征的异质性以及传统RCT设计的使用可能是这些试验失败的潜在原因。有几个因素——包括电子健康记录的广泛采用、获取高维数据成本的降低以及多种潜在治疗方法的可用性——已经发展到能够在HFpEF中实现更具创新性的临床试验设计。在此,我们回顾了HFpEF RCT的当前情况,并提出了几种可在HFpEF中实施的创新性RCT设计,包括富集试验、适应性试验、伞形试验、篮子试验以及基于机器学习的试验(包括每种试验的示例)。我们希望上述创新性试验设计的描述将激发HFpEF临床试验的新方法。

相似文献

1
Innovative Clinical Trial Designs for Precision Medicine in Heart Failure with Preserved Ejection Fraction.
J Cardiovasc Transl Res. 2017 Jun;10(3):322-336. doi: 10.1007/s12265-017-9759-8. Epub 2017 Jul 5.
2
Precision Medicine for Heart Failure with Preserved Ejection Fraction: An Overview.
J Cardiovasc Transl Res. 2017 Jun;10(3):233-244. doi: 10.1007/s12265-017-9756-y. Epub 2017 Jun 5.
4
Advances in the pharmacotherapy of chronic heart failure with preserved ejection fraction: an ideal opportunity for precision medicine.
Expert Opin Pharmacother. 2017 Mar;18(4):399-409. doi: 10.1080/14656566.2017.1288717. Epub 2017 Feb 17.
5
[Heart failure with preserved ejection fraction: an update on diagnosis and treatment].
G Ital Cardiol (Rome). 2020 Feb;21(2):119-127. doi: 10.1714/3300.32705.
6
Tensor Factorization for Precision Medicine in Heart Failure with Preserved Ejection Fraction.
J Cardiovasc Transl Res. 2017 Jun;10(3):305-312. doi: 10.1007/s12265-016-9727-8. Epub 2017 Jan 23.
7
Heart failure with preserved ejection fraction: Classification based upon phenotype is essential for diagnosis and treatment.
Trends Cardiovasc Med. 2018 Aug;28(6):392-400. doi: 10.1016/j.tcm.2018.01.001. Epub 2018 Jan 9.
8
Noncardiac comorbidities in heart failure with preserved ejection fraction - commonly ignored fact.
Circ J. 2015;79(5):954-9. doi: 10.1253/circj.CJ-15-0056. Epub 2015 Feb 25.

引用本文的文献

1
The Rise of Personalized Medicine in Heart Failure Management: A Narrative Review.
Cureus. 2025 May 8;17(5):e83731. doi: 10.7759/cureus.83731. eCollection 2025 May.
2
Evolution of Research on Artificial Intelligence for Heart Failure: A Bibliometric and Visual Analysis.
J Multidiscip Healthc. 2025 May 26;18:2941-2956. doi: 10.2147/JMDH.S525739. eCollection 2025.
3
Computational Phenomapping of Randomized Clinical Trial Participants to Enable Assessment of Their Real-World Representativeness and Personalized Inference.
Circ Cardiovasc Qual Outcomes. 2025 May;18(5):e011306. doi: 10.1161/CIRCOUTCOMES.124.011306. Epub 2025 Apr 22.
4
The Introduction of AI Into Decentralized Clinical Trials: Preparing for a Paradigm Shift.
JACC Adv. 2024 Jul 5;3(8):101094. doi: 10.1016/j.jacadv.2024.101094. eCollection 2024 Aug.
8
Update on Atrial Shunt Therapy for Treatment of Heart Failure.
Struct Heart. 2022 Sep 21;6(6):100090. doi: 10.1016/j.shj.2022.100090. eCollection 2022 Nov.

本文引用的文献

3
Precision Medicine for Heart Failure with Preserved Ejection Fraction: An Overview.
J Cardiovasc Transl Res. 2017 Jun;10(3):233-244. doi: 10.1007/s12265-017-9756-y. Epub 2017 Jun 5.
4
Drug Development for Heart Failure With Preserved Ejection Fraction: What Pieces Are Missing From the Puzzle?
Can J Cardiol. 2017 Jun;33(6):768-776. doi: 10.1016/j.cjca.2017.03.013. Epub 2017 Mar 25.
6
Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction.
Circulation. 2017 Jul 4;136(1):6-19. doi: 10.1161/CIRCULATIONAHA.116.026807. Epub 2017 Apr 5.
9
Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions.
Curr Heart Fail Rep. 2017 Apr;14(2):59-70. doi: 10.1007/s11897-017-0325-0.
10
A Potential PET Radiotracer for the 5-HT Receptor: Synthesis and in Vivo Evaluation of 4-(3-[F]fluorophenethoxy)pyrimidine.
ACS Chem Neurosci. 2017 May 17;8(5):996-1003. doi: 10.1021/acschemneuro.6b00445. Epub 2017 Feb 27.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验